NCT03625128View on ClinicalTrials.gov

18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 2, 2018

Primary Completion Date

August 3, 2018

Study Completion Date

December 3, 2018

Conditions
Alzheimer's DiseaseCortical Basal SyndromeFrontotemporal DementiaProgressive Supranuclear PalsyVascular Cognitive Impairment
Interventions
DRUG

F-18

This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).

Trial Locations (1)

333

Chang Gung Memorial Hospital,Linkou, Taoyuan

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT03625128 - 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls | Biotech Hunter | Biotech Hunter